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SUMMARY
Targeting ‘‘oncogene addiction’’ is a promising strategy for anticancer therapy. We report a potent inhibition
of crucial oncogenes by p53 upon reactivation by small-molecule RITA in vitro and in vivo. RITA-activated p53
unleashes the transcriptional repression of antiapoptotic proteins Mcl-1, Bcl-2, MAP4, and survivin; blocks
the Akt pathway on several levels; and downregulates c-Myc, cyclin E, and b-catenin. p53 ablates c-Myc
expression via several mechanisms at the transcriptional and posttranscriptional level. We show that the
threshold for p53-mediated transrepression of survival genes is higher than for transactivation of proapop-
totic targets. Inhibition of oncogenes by p53 reduces the cell’s ability to buffer proapoptotic signals and
elicits robust apoptosis. Our study highlights the role of transcriptional repression for p53-mediated tumor
suppression.INTRODUCTION
The notion that initial oncogenic lesions remain essential for
tumor maintenance is supported by a number of studies,
including in vivo experiments in mice switching off Myc (Felsher
and Bishop, 1999; Pelengaris et al., 2002), BCR-ABL (Huettner
et al., 2000), or H-ras (Chin et al., 1999). ‘‘Oncogene addiction,’’
i.e., the dependency of tumor cells on oncogenic activity that
initially contributed to tumor phenotype, first coined by Wein-
stein (2002), potentially reveals an ‘‘Achilles’ heel’’ of cancer
cells. Targeting this ‘‘Achilles’ heel’’ is currently a major strategy
for the development of novel anticancer drugs.
Strategies aimed toward restoring the function of the tumor
suppressor p53 have been much less popular so far. Recent
studies in mice with ‘‘switchable’’ p53 demonstrated that resto-
ration of p53 function leads to the suppression of already estab-
lished tumors, such as lymphomas, soft tissue sarcomas, andhepatocellular carcinomas (Martins et al., 2006; Ventura et al.,
2007; Xue et al., 2007). The important conclusion from these
studies is that developed tumors remain vulnerable to p53 resto-
ration. Taken together with the identification of TP53 as the most
commonly mutated gene in a recent systematic study of genetic
alterations in breast and colon cancer (Sjoblom et al., 2006),
these findings firmly support the notion that restoring p53 func-
tion might be an attractive strategy for treating cancer. Reactiva-
tion of p53 appears to be feasible, because p53 protein is usually
expressed in tumors, although it is functionally inert.
Different strategies of p53 rescue for the selective elimination
of tumors could be envisioned, depending on the type of p53
inactivation. Refolding mutant p53 in tumors carrying TP53 point
mutations appears to be a promising approach (Bykov et al.,
2002). In tumors carrying wild-type p53, p53’s function is often
inhibited by MDM2, which binds p53, inhibits its transcriptional
function, and promotes proteasomal degradation of p53 (HauptSIGNIFICANCE
p53 reinstatement leads to impressive regression of established tumors in mice, supporting the idea that restoring p53 is
a good strategy in cancer treatment. Our study adds another dimension to the p53 story, demonstrating that p53 reactiva-
tion triggers ablation of crucial oncogenes. The multitude of oncogenes inhibited by p53 and the multiple levels on which
they are targeted create external robustness of the p53 response. This capability might allow p53 to cope with the daunting
challenge of anticancer therapy: multiple genetic abnormalities in individual cancers. Our finding that a combination of a low
dose of p53-reactivating drug with oncogene inhibitors produced a synergistic effect provides a rationale for drug combi-
nations to minimize side effects and newly developed resistance in patients.Cancer Cell 15, 441–453, May 5, 2009 ª2009 Elsevier Inc. 441
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cules inhibiting the p53/MDM2 interaction or targeting the enzy-
matic activity of MDM2 have been reported (Lain et al., 2008;
Vassilev et al., 2004; Yang et al., 2005). We have identified a small
molecule RITA, which induces p53 accumulation and activation
and suppresses the growth of tumor cells and human tumor
xenografts in mice in a p53-dependent manner without obvious
toxic effects (Issaeva et al., 2004). In addition to serving as lead
compounds for the development of anticancer drugs, p53-reac-
tivating molecules, such as RITA, can be useful tools for the
study of p53 functional activity.
It has been well established that p53 is a transcriptional factor
that regulates the expression of genes involved in control of the
cell cycle and cell death upon activation by genotoxic or onco-
genic stress (Vogelstein et al., 2000). p53 can activate the tran-
scription of the proapoptotic genes PUMA, PMAIP, Bax, Fas,
and others (Vogelstein et al., 2000), along with repression of
the transcription of the survival genes Bcl-2, MAP4, BIRC5 (sur-
vivin), Mcl-1, IGF-1R, MYC, EIF4E, and PIK3CA (Miyashita et al.,
1994; Murphy et al., 1996; Hoffman et al., 2002; Pietrzak and
Puzianowska-Kuznicka, 2008; Werner et al., 1996; Ho et al.,
2005; Zhu et al., 2005; Astanehe et al., 2008). According to the
current view, transrepression by p53 might occur via different
mechanisms, including steric interference, squelching of the tran-
scriptional activators, and p53-mediated recruitment of histone
deacetylases (Riley et al., 2008). However, the relative contribu-
tion of transactivation and transrepression functions in the p53-
induced biological response has not been established yet.
The question of how p53 chooses between its different targets
received great attention, due to its paramount relevance to
cancer therapy (Oren, 2003). The response of cells to p53 can
vary greatly depending on a cellular context, the key component
being the presence of survival signals, which render cells resis-
tant to apoptosis. The overexpression of factors blocking
apoptosis downstream of p53, such as Mcl-1 or Bcl-2, might
lead to escape from p53-induced cell death. It is believed that
when survival signals prevail, p53 activation will more likely result
in growth arrest (Lowe et al., 2004; Oren, 2003). Thus, it remains
to be elucidated whether p53 activation can counteract survival
signaling, which is persistently expressed in cancer cells.
Using the p53-reactivating molecule RITA, we addressed the
questions of whether and how p53 can overcome antiapoptotic
and survival signals. We demonstrate that p53 activated by RITA
represses the set of prosurvival oncogenes that play a critical
role in p53-induced apoptosis.
RESULTS
Transcriptional Repression of Oncogenes
upon p53 Reactivation by RITA
To explore the effects of restoring p53 function in tumor cells, we
analyzed the changes in gene expression in isogenic p53-posi-
tive and p53 null HCT116 colon carcinoma cells after treatment
with 1 mM RITA by using genome-wide DNA microarrays (Affy-
metrix; for details, see Enge et al. [2009]). Upon RITA treatment,
a significant number of genes were downregulated in a p53-
dependent manner, including the oncogenes IGF-1R, PIK3CA,
PIK3CB, MYC, EIF4E, BCL-2, MAP-4, and MCL-1 (Figure 1A).
To test whether a similar effect occurs in a tumor cell line of442 Cancer Cell 15, 441–453, May 5, 2009 ª2009 Elsevier Inc.a different origin, we performed a DNA microarray experiment
in breast carcinoma MCF7 cells addressing the kinetics of tran-
scriptional repression upon RITA treatment (Figure 1B). We
observed a very good correlation with the HCT116 microarray
data. p53 reactivation resulted in strong transcriptional repres-
sion of the same set of oncogenes, with the exception of EIF4E
and MAP-4, whose levels were not affected.
To verify our microarray data, we examined the mRNA levels of
these genes by quantitative real-time PCR (qPCR). We observed
a marked downregulation of the mRNA levels of IGF-1R, PIK3CA,
PIK3CB,MYC,EIF4E,BCL-2,MAP-4, andMCL-1 in both HCT116
and in MCF7 cells (Figures 1C and 1D, respectively). According
to qPCR, transcriptional repression of oncogenes was much
stronger in MCF7 cells, compared with HCT116 cells.
Transrepression of oncogenes was dependent on p53,
because we did not detect any changes in the expression of
these genes after RITA treatment in the p53 null cell lines
HCT116 TP53/ (Figure 1C), Saos-2, and H1299 (Figure 1E).
In order to address p53 dependence in MCF7 cells, we blocked
p53 function by using the small-molecule p53 inhibitor pifithrin-a
(Komarov et al., 1999) or p53shRNA. Pifithrin-a was a superior
p53 inhibitor compared to p53 depletion by shRNA, completely
blocking p53 induction by RITA, whereas p53shRNA had only
a partial effect (Figure 2A and Figure S1A available online,
respectively); therefore, we used pifithrin-a in our subsequent
experiments. Repression of the oncogenes by p53 (Figure 1D)
in MCF7 cells, as well as transactivation of p53 targets (data
not shown), was efficiently prevented by pifithrin-a, supporting
the notion that downregulation of oncogenes is p53 dependent.
In general, we observed a very good correlation of microarray
data with qPCR in both cell lines, with the exception of EIF4E,
whose repression in MCF7 cells was detected by qPCR, but
not by microarray. In addition, qPCR showed a clear p53-depen-
dent reduction of expression of another p53 target gene, BIRC5
(survivin) in both cell lines (Figures 1C and 1D), which was not
detected in microarray experiments. These differences probably
reflect a poor hybridization with the probes in the array.
Consistent with the decrease of mRNA levels, protein levels of
IGF-1R, c-Myc, survivin, and Mcl-1 were downregulated by RITA
inwild-typep53-expressingHCT116,MCF7,A549,andU2OScells,
but not in the p53 null cell lines HCT116 TP53/, Saos-2, and
H1299 and in cells pretreated with pifithrin-a (Figures 2A and 2B).
Importantly, the transcriptional program resulting in oncogene
inhibition by p53 was not restricted to the in vitro phenomenon.
We applied RITA to HCT116 and HCT116 TP53/ xenografts in
SCIDmice. Upon 18 hr of RITA treatment, we observed a decline
of c-Myc, Mcl-1, survivin, and IGF-1R in p53-positive, but not
p53-negative tumors (Figure 2C).
Taken together, our results demonstrate that reactivation of
p53 by RITA markedly ablated the expression of a set of impor-
tant oncogenes in tumor cells in vitro and in vivo. Because most
of these factors are crucial for the viability of both tumor and
normal cells, it appears important to assess the effect of RITA
on this set of genes in nontransformed cells.
RITA Does Not Affect the Expression of Survival Genes
in Nontransformed Cells
We examined the effect of RITA on survival genes in several non-
transformed cell lines: human diploid fibroblasts (HDFs); and two
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IGF1R, c-Myc, Mcl-1, and survivin were not affected by
RITA in these cell lines (Figure 2D). This was matched by
the lack of induction of p53 and its target gene PUMA, in
line with the absence of p53 activation in nontransformed
fibroblasts and lymphocytes, reported by us previously (Is-
saeva et al., 2004). The viability of nontransformed cell lines
was not affected by RITA either (Figure 2E; Figure S1B).
However, the chemotherapeutic agent 5-fluorouracil (5-FU),
known to cause DNA damage, induced p53 and PUMA in
these cells and reduced the expression of c-Myc and survivin
(Figure 2D), along with the induction of cell death (Figure 2E;
Figure S1B). We therefore conclude that targeting p53 by
RITA does not result in p53 activation and/or block of survival
gene expression in nontransformed cells, in contrast to DNA-
damaging drugs. Tumor-selective inhibition of proproliferative
and antiapoptotic genes might provide a powerful weapon
against cancer cells without evoking toxic effects in normal
tissues. Thus, we set out to explore in more detail the down-
Figure 1. p53-Induced Transcriptional
Repression of a Set of Oncogenes
(A) Microarray analysis of gene expression in
wtp53-expressing HCT116 and p53 null HCT116
TP53/ after 4 hr and 12 hr of treatment with 1 mM
RITA. Shown is the heatmap of genes differentially
expressed at 1% FDR, F-test. Vertical rows indi-
cate separate arrays, and horizontal rows indicate
genes. Values are normalized by row. Green indi-
cates low expression; red indicates high expres-
sion.
(B) Microarray analysis of MCF7 cells treated with
1 mM RITA for 2–24 hr presented as in (A). Values
are normalized to untreated control.
(C) mRNA levels of oncogenes were detected by
qPCR in HCT116 and HCT116 TP53/ cells 4
and 8 hr after treatment with 1 mM RITA (mean ±
SEM, n = 3).
(D) mRNA levels of oncogenes were detected by
qPCR in untreated MCF7 cells or upon pretreat-
ment with 10 mM of the p53 inhibitor pifithrin-a 4
and 8 hr after RITA treatment (mean ± SEM, n = 3).
(E) mRNA levels of oncogenes in p53 null Saos-2
and H1299 cells, as detected by qPCR 4 and
8 hr after RITA treatment (mean ± SEM, n = 3).
stream effects of RITA-induced inhibi-
tion of oncogenes in tumor cells
and the contribution of oncogene inhibi-
tion to the p53-mediated biological
response.
Inhibition of Key Downstream
Players of the Akt Pathway
Pathway analysis of microarray data
obtained in HCT116 cells identified
the PI(3)K/Akt pathway as one of the
most affected by RITA (Enge et al.,
2009). Indeed, we found that several
genes involved in Akt signaling were
repressed, as illustrated in Figure 3A.
These include IGF-1R, EIF4E, as well as PIK3CA and PIK3CB,
which encode catalytic subunits of PI(3) kinase, p110a and
p110b, respectively (for the details of the Akt pathway, see
Figure 3A).
Next, we examined whether inhibition of IGF-1R and PI(3)K
affects the abundance and phosphorylation status of down-
stream factors. Upon treatment with RITA, we observed a p53-
dependent decline of the active, phosphorylated form of Akt
kinase, as well as phosphorylated mTOR downstream of Akt
(Figures 3B and 3C). Furthermore, Akt kinase activity was sig-
nificantly reduced in RITA-treated cells, as manifested by a
decreased ability of Akt to phosphorylate its substrate GSK3ab
in vitro (Figure 3G).
Along with inhibition of mTOR phosphorylation, mRNA of
EIF4E, one of the important downstream mediators of mTOR,
was significantly downregulated (Figures 1A, 1C, and 1D).
Because eIF4E is implicated in the regulation of translation of
several important oncoproteins, including c-Myc (Averous and
Proud, 2006), we set out to investigate whether inhibition ofCancer Cell 15, 441–453, May 5, 2009 ª2009 Elsevier Inc. 443
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RITA treatment.
We employed a translational reporter construct, encoding
a luciferase whose mRNA translation is CAP dependent and regu-
lated by eIF4E. Indeed, CAP-dependent translation was inhibited
by RITA in p53-positive cells, but not in p53 null cells (Figure 3D).
However, we did not observe a general inhibition of translation, as
growth suppressor proteins were induced upon RITA treatment
(Figure 3E). Notably, ectopic expression of eIF4E alleviated the
block of CAP-dependent translation (Figure 3D), supporting the
notion that the effect is eIF4E dependent.
Next, we assessed whether eIF4E can rescue the decline of
oncoproteins by RITA (Figure 3F). Ectopic expression of eIF4E
conferred only partial protection of the c-Myc level at a late
time point (24 hr), indicating a minor contribution of translational
block to c-Myc depletion. Downregulation of Mcl-1 was not
restored at all. Unexpectedly, we observed a potent rescue of
IGF-1R level upon eIF4E overexpression, indicating that in addi-
tion to repression of IGF-1R transcription, p53 induces downre-
gulation of IGF-1R protein via an eIF4E-dependent mechanism.
Subsequently, we studied the status of another downstream
target of Akt, GSK-3b (Figure 3A). In accordance with inhibition
of Akt activity (Figure 3G), phosphorylation of endogenous
Figure 2. p53-Dependent Downregulation
of the Oncoproteins c-Myc, IGF-1R, Mcl-1,
and Survivin In Vitro and In Vivo
(A) Immunoblotting of IGF-1R, c-Myc, Mcl-1, and
survivin in cell extracts from the wtp53 cell lines
U2OS, MCF7, A549, and HCT116 treated with
RITA or with RITA in combination with pifithrin-a.
(B) Immunoblotting of oncoproteins in cell extracts
from p53 null Saos-2 and H1299 cells, treated or
nontreated with RITA.
(C) Protein levels of IGF-1R, c-Myc, survivin, and
Mcl-1 upon 18 hr of RITA treatment (1 mg/kg) of
HCT116 and HCT116 TP53/ tumor xenografts
in SCID mice, as detected by immunoblotting.
(D) Protein levels of oncoproteins in nontrans-
formed human diploid fibroblasts (HDFs) and the
mammary epithelial cell lines MCF10A and
184A1 upon 12 hr treatment with 1 mM RITA or
100 mM 5-FU was detected by western blot.
(E) Phase-contrast microscopy of nontransformed
MCF10A and 184A1 cells treated with 1 mM RITA
or 100 mM 5-FU for 48 hr. Scale bars represent
100 mm.
GSK3b was reduced by RITA in HCT116
cells, but not in p53 null cells (Figure 3H).
Rescue of GSK3b activity due to inhi-
bition of Akt is expected to result in
proteasomal degradation of GSK3b
substrates. Indeed, as shown in Fig-
ure 3I, activation of p53 by RITA led
to a profound downregulation of the
GSK3b substrates c-Myc, b-catenin (Do-
ble and Woodgett, 2003), Mcl-1 (Maurer
et al., 2006), and cyclin E (Figures 4G
and 4H) in a p53-dependent manner. In
line with these findings, GSK3b-dependent phosphorylation of
c-Myc was increased (Figure 4D), supporting the notion that
GSK3b activity is induced by RITA.
p53 Induces GSK3b-Dependent Degradation of c-Myc
The data presented above suggest that, in addition to transcrip-
tional repression of MYC (Figures 1A–1D), c-Myc might also be
targeted at a protein level due to phosphorylation by GSK3b.
To address the impact of a posttranscriptional mechanism on
c-Myc inhibition, we tested whether c-Myc expressed from
a p53-independent promoter will be affected. RITA treatment re-
sulted in strong reduction of overexpressed ectopic c-Myc, indi-
cating regulation on a posttranscriptional level (Figure 4A).
Next, we examined the involvement of proteasomal degrada-
tion in the depletion of c-Myc. The proteasomal inhibitor MG132
partially prevented downregulation of c-Myc by RITA (Figure 4B;
Figure S2A). Consistent with these data, we observed a decrease
in c-Myc half-life upon p53 activation by RITA (Figure 4C).
However, the stability of Mcl-1, another putative target of
GSK3b, was not decreased (Figure S2B). Thus, p53 appears to
unleash the proteasomal degradation of c-Myc, but not of Mcl-1.
In order to validate whether GSK3b is required for c-Myc
downregulation, we blocked GSK3b activity by the specific444 Cancer Cell 15, 441–453, May 5, 2009 ª2009 Elsevier Inc.
Cancer Cell
Inhibition of Oncogenes by RITA-Reactivated p53inhibitor B1686 BIO. This resulted in a partial rescue of c-Myc
levels, evident at 8 hr after RITA treatment (Figure 4E). However,
after 24 hr, c-Myc levels were reduced to the same level as in the
absence of the GSK3b inhibitor, presumably due to the tran-
scriptional repression of MYC.
In contrast to c-Myc, the level of Mcl-1 was not rescued by
B1686 BIO (Figure 4E), indicating that downregulation of Mcl-1
by RITA is not GSK3b dependent. Taken together with our results
presented above, that stability or translation of Mcl-1 were not
affected by RITA, this allowed us to conclude that the observed
decline of Mcl-1 protein occurs only on an mRNA level. On the
other hand, c-Myc is targeted for degradation, at least partially
due to GSK3b-induced phosphorylation.
Impact of the p53 Target Fbxw7/hCdc4 on c-Myc
and Cyclin E Downregulation
GSK3b-phosphorylated c-Myc is a substrate for the F box
protein Fbxw7/hCdc4, the substrate specificity factor of
SCFFbxw7/hCdc4 E3 ubiquitin ligase (Yada et al., 2004). Microarray
analysis (Figure 1A) and qPCR (Figure 4F) showed that the mRNA
levels of two FBXW7/hCDC4 isoforms (b and g) were significantly
Figure 3. p53-Dependent Inhibition of the
Akt Pathway upon RITA Treatment
(A) Scheme depicting the major players in the
PI(3)K/Akt pathway and oncogenes that are tran-
scriptionally repressed upon RITA treatment (in
bold).
(B) Levels of IGF-IR and phosphorylated Akt
HCT116 and HCT116 TP53/ cells were analyzed
by western blot.
(C) Phosphorylation of mTOR upon RITA treatment
was assessed by western blot.
(D) Effect of RITA on CAP-dependent translation
was evaluated by using the luciferase translation
reporter in the presence or absence of ectopic
expression of eIF4E (mean ± SEM, n = 4).
(E) Levels of GADD45a, Fas, and p53 proteins
were detected by western blot.
(F) IGF-IR, c-Myc, and Mcl-1 protein levels upon
1 mM RITA in the presence or absence of ectopic
expression of eIF4E in HCT116 cells, as detected
by immunoblotting.
(G) Akt kinase activity was determined by an
in vitro kinase assay with Akt kinase immunopre-
cipitated from HCT116 and HCT116 TP53/ cells
and purified GST-GSK3ab as a substrate. Phos-
phorylation of GST-GSK3ab was analyzed by
western blot with phospho-specific antibodies.
(H) Phosphorylation of cellular GSK3b upon treat-
ment with 1 mM RITA of HCT116 and HCT116
TP53/ cells was assessed by immunoblotting
with phospho-specific antibodies.
(I) p53-dependent downregulation of the GSK3b
substrates b-catenin, c-Myc, and Mcl-1 upon
treatment with 1 mM RITA was analyzed by
western blot.
upregulated by RITA in a p53-dependent
manner. Induction of the b isoform is
consistent with published data demon-
strating that the FBXW7/hCDC4 gene is
a direct p53 target (Kimura et al., 2003), whereas the g isoform
has not yet been demonstrated to be regulated by p53.
Inorder toexamine the impactofFbxw7/hCdc4onc-Mycdegra-
dation, we compared the levels of c-Myc upon RITA treatment of
HCT116 and HCT116 hCDC4/ cells in which the FBXW7/
hCDC4 gene has been deleted. In the absence of Fbxw7/hCdc4,
the kinetics and extent of c-Myc depletion were significantly
impeded, confirming the involvement of Fbxw7/hCdc4 (Figure 4G).
Nevertheless, the level of c-Myc was not completely rescued in
these cells upon p53 reactivation by RITA, supporting our data
that more than one mechanism contributes to c-Myc downregula-
tion. Importantly, the level of another critical oncoprotein, cyclin E,
a well established substrate for the SCFFbxw7/hCdc4 E3 ubiquitin
ligase (Strohmaier et al., 2001), was downregulated in a p53-
dependent manner (Figure 4H). Contrary to c-Myc, cyclin E was
completely rescued byFbxw7/hCdc4 deficiency (Figure 4G), impli-
cating Fbxw7/hCdc4 as the major factor contributing to cyclin E
decline. However, deletion of FBXW7/hCDC4 was not sufficient
to protect cells from growth inhibition by RITA, as shown by using
a short-term cell proliferation assay and a long-term colony forma-
tion assay (Figure 4I, left and right panels, respectively).Cancer Cell 15, 441–453, May 5, 2009 ª2009 Elsevier Inc. 445
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gers proteasome-dependent degradation of c-Myc and cyclin E.
Dose-Dependent Repression of Oncogenes by RITA
Our results suggest that pharmacologically reactivated p53 acts
as a potent repressor of a number of oncogenic and survival
factors, as well as functions as a powerful trigger of proapoptotic
proteins (Figure 5A) (Enge et al., 2009). Furthermore, we found
that the transactivation of proapoptotic genes requires a lower
dose of RITA than transrepression of prosurvival genes. As
evident from Figure 5A, the response to 0.1 and 1 mM RITA
was quite similar in terms of induction of p53 and its targets
PUMA and Noxa. In contrast, oncogenes were regulated differ-
ently: whereas 1 mM RITA was sufficient to trigger a sharp down-
regulation of c-Myc, Mcl-1, and survivin, upon treatment with
0.1 mM RITA the decline of these oncogenes was either absent
or less pronounced (Figure 5B).
qPCR confirmed that the transcriptional repression of MCL-1,
MYC, BIRC5, EIF4E, PIK3CA, and PIK3CB was fully unleashed
Figure 4. Reactivation of p53 by RITA
Induces Proteasomal Degradation of c-Myc
via Activation of GSK3b and Fbxw7/hCdc4
(A) The level of c-Myc expressed under a Tet-reg-
ulatable promoter in U2OS-Myc cells treated or
nontreated with RITA was detected by western
blot.
(B) Immunoblotting of c-Myc upon proteasomal
inhibition with MG132 combined with RITA treat-
ment.
(C) Half-life of c-Myc after RITA treatment, as as-
sessed by immunoblotting of c-Myc upon treat-
ment with cycloheximide for the indicated periods.
(D) Western blot of phosphorylated c-Myc 2 and
4 hr after treatment with 1 mM RITA. HCT116 cells
were pretreated with MG132 to prevent downre-
gulation of c-Myc.
(E) c-Myc and Mcl-1 levels upon RITA treatment
combined with inhibition of GSK3b with B1686
BIO, as detected by immunoblotting.
(F) mRNA levels of b and g isoforms of FBXW7/
hCDC4 in HCT116 cells were detected by qPCR
(mean ± SEM, n = 3).
(G) c-Myc and cyclin E levels in HCT116 CDC4/
cells after RITA treatment as assessed by western
blot.
(H) Cyclin E levels in wtp53 expressing U2OS and
MCF7 and in p53 null Saos-2 cells were detected
by western blot.
(I) Growth suppression by RITA was assessed by
a cell proliferation assay (left panel) (mean ± SEM,
n = 3) and a long-term colony formation assay in
HCT116 and HCT116 CDC4/ cells (right panel).
at 1, but not at 0.1 mM, in both HCT116
and MCF7 cells, whereas p53 target
genes encoding p21 and Noxa were
readily induced at a low dose (Figures
5C and 5D).
Notably, in the absence of oncogene
inhibition at 0.1 mM RITA, tumor cells
died much less efficiently compared to
1 mM (Figure 7A), indicating that inhibition of oncogenes contrib-
utes to apoptosis induction by p53. To rule out the possibility that
downregulation of survival factors was a consequence of
apoptosis and/or caspase activation, we examined their level
upon blocking apoptosis by the pan-caspase inhibitor Z-VAD-
fmk. Caspase inhibition did not prevent the downregulation of
Mcl-1, survivin, and c-Myc by RITA (Figure 5E), supporting the
notion that their decline is due to p53-mediated transcriptional
repression.
To address the differences underlying the regulation of proa-
poptotic and prosurvival genes by p53, we examined the subcel-
lular distribution of p53 upon treatment with0.1 and1mM RITA.We
repeatedly noted a striking disproportion in the subnuclear distri-
bution of p53 upon these two doses of RITA. Abundance of p53 in
the chromatin-bound fraction was greatly enhanced by 1, but not
by 0.1 mM, RITA (Figure 6A). Thus, a higher level of p53 on chro-
matin triggered by 1 mM RITA correlated with the induction of
transrepression by p53. As a reference transcriptional factor impli-
cated in both transcriptional activation and transcriptional446 Cancer Cell 15, 441–453, May 5, 2009 ª2009 Elsevier Inc.
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distribution of c-Myc. c-Myc was also present in the chromatin
fraction in untreated control cells (Figure 6A), whereas its level
was reduced in treated cells, in line with results demonstrated
above.
Recent chromatin immunoprecipitation (ChIP) studies demon-
strated that p53 is already bound to most of its target genes in
cancer cells before the genotoxic stress (Kaeser and Iggo, 2002;
Shaked et al., 2008). However, in spite of being present at the
promoters, p53 is not fully active as a transcriptional factor in the
absence of stress, suggesting the involvement of a p53 inhibitor
that blocks p53 function directly on promoters. A possible candi-
date for this role is MDM2, which can associate with chromatin in
a p53-dependent manner (Minsky and Oren, 2004; White et al.,
2006). We therefore tested whether the presence of MDM2 on
chromatin is affected by RITA. We readily detected MDM2 in the
chromatin fraction in nontreated MCF7 and HCT116 cells
(Figure 6B). The amount of MDM2 in this fraction decreased
upon RITA treatment, mirroring the increase of chromatin-bound
p53 (Figure 6B). However, although both concentrations of RITA
reduced the amount of p53/MDM2 complexes and induced p53
accumulation in the soluble fraction to the same extent (Figures
5A and 5B; Figures S3A and S3B), a lower dose of RITA was less
efficient in releasing MDM2from chromatin-bound p53 (Figure6B).
Figure 5. Dose-Dependent Effect of RITA
on the Transcriptional Activation of Proa-
poptotic Genes and the Repression of
Oncogenes
(A) Levels of proapoptotic factors Puma and Noxa
upon 0.1 and 1 mM RITA in HCT116 and MCF7
cells were detected by immunoblotting.
(B) Immunoblot of p53, c-Myc, Mcl-1, and survivin
in HCT116 and MCF7 cells after treatment with 1
and 0.1 mM RITA.
(C and D) Upper panels: mRNA levels of MCL-1,
MYC, BIRC5, EIF4E, PIK3CA, and PIK3CB after
1 and 0.1 mM RITA as detected by qPCR. Lower
panels: mRNA levels of CDKN1A and PMAIP after
0.1 mM RITA. Experiments in (C) and (D) were per-
formed in HCT116 and MCF7 cells treated with
RITA for 12 and 8 hr, respectively (mean ± SEM,
n = 3).
(E) Levels of c-Myc, Mcl-1, and cleaved PARP
upon treatment with RITA combined with the cas-
pase inhibitor zVAD (80 mM).
Furthermore, we compared the relative
abundance of p53 and MDM2 on p53-acti-
vated versus p53-repressed promoters by
using ChIP. We found that in untreated
cells, the p53/MDM2 ratio on the p53-acti-
vated CDKN1A promoter was significantly
higher than on p53-repressed MCL-1
promoter (Figure 6C). Treatment with
0.1 mM RITA increased the p53/MDM2
ratio on CDKN1A, but not on the MCL-1
promoter (Figure 6D), whereas 1 mM RITA
increased the p53/MDM2 ratio on both
promoters (Figure 6D). Taken together,
our results are consistent with the idea that MDM2 is more easily
dislocated by RITA from p53-activated than from p53-repressed
promoters. It is therefore possible that transactivation of p53 might
be less tightly controlled by MDM2 than transrepression. If this is
the case, the prediction is that the basal levels of expression of
survival genes that p53 can repress should be similar in the
absence and presence of p53, whereas the expression of at least
some p53-transactivated genes should be higher in p53-positive
cells. Indeed, the analysis of microarray data of the gene expres-
sion profiles of untreated HCT116 and HCT116 TP53/ cells re-
vealed a significant difference between the basal levels of
expression of these two groups of genes. A number of genes
known to be positively regulated by p53, including CDKN1A,
FAS, DDB2, and others had a higher level of expression in
p53-positive than in p53 null cells. On the contrary, the mRNA
levels of the p53-repressed genes IGF1R, MYC, EIF4E, BCL2,
MAP4, MCL1, and BIRC5 did not differ between the lines
(Figure 6E).
Taken together, our data suggest that p53-mediated transre-
pression is more tightly controlled than transactivation; MDM2
associated with chromatin might play an important part in this
process. The dose-dependent effect of RITA on the expression
of oncogenes appears to be due to a less efficient release of
MDM2 from the promoters of p53-repressed genes.Cancer Cell 15, 441–453, May 5, 2009 ª2009 Elsevier Inc. 447
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of Apoptosis by p53
To address whether the inhibition of oncogenes is essential
for the apoptosis induction by p53, we used genetic and phar-
macological approaches. We selected three representative
oncogenes—prosurvival and proproliferation factor Akt, propro-
liferative c-Myc, and antiapoptotic Mcl-1—and ‘‘restored’’ their
depletion at 0.1 mM RITA by applying a chemical inhibitor or cor-
responding siRNA.
Downregulation of Mcl-1 by siRNA, although it exerted only
a weak proapoptotic effect per se, synergized with 0.1 mM
RITA in apoptosis induction (Figures 7B–7D; Figures S4A and
S4B). The effect of c-Myc ablation was also synergistic, albeit
less pronounced (Figures 7B–7D; Figures S4A and S4B).
Furthermore, we examined whether the downregulation of
survival genes plays a role in apoptosis induction by another
known p53 activator, nutlin3a (Vassilev et al., 2004). The effect
of nutlin3a on survival genes was not prominent in MCF7,
U2OS, and HCT116 lines (Figure 7E). Nutlin3a caused a decline
of c-Myc and survivin in MCF7 cells, but not in U2OS and
Figure 6. Dose-Dependent Differences in
the Subcellular Distribution of p53 Correlate
with Distinct Transcriptional Programs
Induced by p53
(A) Cytoplasmic fraction, soluble nuclear fraction
(extracted with 300 mM NaCl), and chromatin-
bound fraction (nuclear pellet after extraction)
were obtained from MCF7 cells treated with 0.1
and 1 mM RITA and analyzed by immunoblotting.
We used actin as a marker and loading control
for the cytoplasmic fraction, PARP for both the
soluble nuclear and chromatin-bound fractions,
and Histone H3 for the chromatin-bound fraction.
A cell-equivalent amount of each fraction was
used for the comparisons.
(B) Abundance of p53 and MDM2 on chromatin
upon treatment with 0.1 and 1 mM RITA was de-
tected as in (A).
(C) The ratio between p53 and MDM2 bound to
MCL-1 and CDKN1A promoters in untreated
HCT116 cells was detected by chromatin immu-
noprecipitation (ChIP).
(D) Changes in the p53/MDM2 ratio on MCL-1 and
CDKN1A promoters upon treatment with 0.1 and
1 mM RITA were detected by ChIP.
(E) Basal levels of mRNAs of p53-transactivated
and p53-repressed genes were estimated using
microarray analysis of HCT116 and HCT116
TP53/ cells (mean ± SEM, n = 3).
HCT116 lines, whereas IGF1R and Mcl-
1 were not affected at all (Figure 7E).
These three lines are known to be only
partially susceptible to nutlin3a-induced
apoptosis (Enge et al., 2009; Tovar
et al., 2006). However, in nutlin3a-sensi-
tive SJSA cells, Mcl-1 is downregulated
(Wade et al., 2008). To evaluate whether
the depletion of Mcl-1 or c-Myc will affect
the response to nultin3a, we combined
nutlin3a with siRNA to c-Myc or Mcl-1.
Indeed, depletion of c-Myc or Mcl-1 synergized with nutlin3a in
cell killing (Figure 7E), confirming that downregulation of c-Myc
and Mcl-1 plays an important role in the apoptosis induced
upon pharmacological reactivation of p53.
Next, we tested whether inhibition of the PI(3)K-Akt pathway
contributes to p53-mediated cell death. Blocking the PI(3)K
pathway by the pharmacological inhibitor LY294002 induced
a low number of apoptotic cells, similarly to 0.1 mM RITA (Figures
7F and 7G; Figure S4C). Notably, a combination of both treat-
ments induced apoptosis much more efficiently, in a synergistic
manner, indicating that the lack of inhibition of the PI(3)K
pathway by 0.1 mM RITA impedes efficient apoptosis induction.
Taken together, our data imply that ablation of oncogenes and
survival factors plays an important role in the induction of
apoptosis by pharmacologically reactivated p53.
DISCUSSION
Given the pivotal role of apoptosis in successful anticancer
therapy, it is of crucial importance to understand the448 Cancer Cell 15, 441–453, May 5, 2009 ª2009 Elsevier Inc.
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cell death and, in particular, to p53-mediated apoptosis. Here,
we applied the p53-reactivating compound RITA (Issaeva
et al., 2004) to further decipher the consequences of restoration
of p53 function in tumor cells. We previously demonstrated that
transactivation of proapoptotic genes is required for cell death
induced by RITA-reactivated p53 (Enge et al., 2009). In the
present study, we show that upregulation of proapoptotic
targets is not sufficient for a full-scale induction of cell death
by RITA. We found that p53 triggers a dramatic and rapid down-
regulation of a number of critical oncogenes, thus overcoming
survival signaling. Functional studies demonstrated that this
facet of p53 activity is critical for a robust induction of apoptosis
by pharmacologically reactivated p53.
Importantly, our results indicate that induction of proapoptotic
genes and inhibition of antiapoptotic/survival genes represent
two branches of the p53 response, which are differentially regu-
lated. Evidence for this comes from the dose-dependent exper-
Figure 7. Inhibition of Oncogenes Plays a
Significant Role in Apoptosis Induction by
Pharmacologically Activated p53
(A) Detection of apoptotic cells by FACS of
annexin-stained HCT116 and MCF7 cells after
24 hr of treatment with 0.1 and 1 mM RITA and
by phase-contrast microscopy of MCF7 cells.
(B and C) Cell death induction was assessed by
trypan blue staining of cells treated with a low
dose of RITA upon knockdown of c-Myc and
Mcl-1 by siRNA in (B) HCT116 and (C) MCF7 cells
(mean ± SEM, n = 3).
(D) Phase-contrast microscopy of MCF7 cells
treated with 0.1 mM RITA upon c-Myc or Mcl-1
knockdown. Scale bars represent 100 mm.
(E) Upper panel: levels of IGF1R, c-Myc, Mcl-1,
survivin, and p53 in MCF7, U2OS, and HCT116
cells treated with 10 mM nutlin3a were assessed
by western blot. Lower panel: cell death induced
by nutlin3a in the presence or absence of c-Myc
or Mcl-1 depletion by siRNA was detected by try-
pan blue staining (mean ± SD, n = 3).
(F and G) Cell death of HCT116 cells treated with
the indicated combinations of RITA and the PI3-
kinase inhibitor LY294002 was assessed by (F) try-
pan blue staining (mean ± SD, n = 3) or (G) phase-
contrast microscopy.
The scale bars in (A), (G), and (D) represent
100 mm. The asterisk in (B), (C), (E), and (F) denotes
an expected additive effect.
iments showing induction of proapop-
totic factors in the absence of
transcriptional repression of survival
genes at a submicromolar concentration
of RITA. We show that induction of the
transcriptional repression program corre-
lated with a higher p53/MDM2 ratio on
chromatin as a result of increased p53
and reduced MDM2 abundance on chro-
matin. Previous studies demonstrated
that p53-dependent association of
MDM2 on chromatin blocks transcrip-
tional activation by p53 (Minsky and Oren, 2004; White et al.,
2006). It has only begun to be examined how p53 and MDM2
interrelate on chromatin. Interesting mechanism of blocking
p53 transcriptional activation on the promoters has been discov-
ered (Minsky and Oren, 2004), which is mediated by MDM2-
dependent ubiquitination of histones; there are likely to be other
mechanisms. Our results suggest that p53-mediated transre-
pression is controlled more tightly than transactivation and
involves MDM2 associated with the promoters of p53-repressed
genes. The mechanism(s) by which MDM2 blocks transrepres-
sion by p53 awaits further investigation. It is possible that asso-
ciation of MDM2 with promoters of p53-repressed genes might
favor recruitment of histone acetylases, such as p300, instead
of histone deacetylases. In spite of intensive research, the mech-
anisms behind p53-mediated transcriptional repression remain
largely unknown (Laptenko and Prives, 2006; Riley et al.,
2008). Dose-dependent induction of p53-mediated transactiva-
tion versus transrepression by RITA might provide a new toolCancer Cell 15, 441–453, May 5, 2009 ª2009 Elsevier Inc. 449
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sion.
A number of p53-repressed genes that play a role in cell
survival have been identified in previous studies (Laptenko and
Prives, 2006; Oren, 2003). However, it is still unclear whether re-
activation of p53 can overcome survival signaling in cancer cells.
Our data suggest that only upon simultaneous engagement of
both branches, i.e., activation of proapoptotic genes and inhibi-
tion of survival genes, can an efficient apoptotic response can be
elicited. This is consistent with recently published in vivo data,
suggesting that other p53 functions, such as transcriptional
repression, may be the key to an efficient apoptotic response.
It has been shown that the VP16-p53 chimeric protein displayed
profound apoptotic defects in a variety of settings, despite being
fully competent in the transcriptional upregulation of proapop-
totic genes (Johnson et al., 2008).
Based on our results, we propose a model in which two
distinct p53-dependent transcriptional programs are required
to trigger a full-scale apoptotic response (Figure 8). Our data
suggest that induction of just one branch, i.e., enhanced expres-
Figure 8. Model: Two Branches of the p53 Transcriptional Program
Are Required for Efficient Apoptosis Induction
Upper panel: a low dose of RITA can displace MDM2 from p53 proapoptotic
targets, but is insufficient to displace MDM2 from p53-repressed survival
genes. Transcriptional activation of the proapoptotic p53 targets PUMA,
Noxa, Fas, and Bax is counteracted by prosurvival signaling, blocking
apoptosis at the submicromolar dose of RITA. Lower panel: 1 mM RITA effi-
ciently dislocates MDM2 both from p53-activated target genes and from
p53-repressed targets. This triggers the transcriptional repression of prosur-
vival and proproliferative oncogenes by p53. Simultaneous activation of proa-
poptotic genes and repression of oncogenes results in robust apoptosis.450 Cancer Cell 15, 441–453, May 5, 2009 ª2009 Elsevier Inc.sion of proapoptotic proteins, might be insufficient to shift the
survival/death balance and to produce a robust apoptotic
outcome. Concurrent downregulation of prosurvival factors
might work in concert with the upregulation of proapoptotic
factors to cross a threshold for firing the apoptotic program,
because only when proapoptotic factors outweigh the prosur-
vival buffer can the program run to completion. In addition to
the degradation of p53, MDM2 controls both branches of the
p53-mediated response directly on promoters of p53 target
genes. The threshold for displacing MDM2 from p53-repressed
genes is higher than that for p53-activated genes. This creates
an additional level of regulation of the p53 choice between the
life and death of a cell.
Our results show that the initial transcriptional repression of
individual genes by p53 unleashes a cascade of events leading
to inhibition of oncogenic factors at several different levels,
including transcriptional, translational, and posttranslational
changes. Reactivated p53 represses transcription of the anti-
apoptotic target genes BCL-2, MCL-1, and BIRC5 (survivin)
and a set of target genes encoding upstream and downstream
components of the Akt survival pathway, IGF-1R, PIK3CA, and
EIF4E. Consequently, the block of PI(3)K signaling and inhibition
of Akt phosphorylation/activity induce pleiotropic effects and
result in profound changes in the survival program. As a result
of mTOR and eIF4E inhibition, translation of c-Myc and IGF-1R
mRNAs was also decreased. Moreover, active GSK3b promoted
the proteasomal degradation of its downstream targets c-Myc,
cyclin E, and b-catenin, which was facilitated by p53-mediated
induction of the E3 ubiquitin ligase Fbxw7/hCdc.
We believe that the pleiotropic effect of p53 on c-Myc, i.e.,
repression of c-Myc transcription, block of its translation, and
induction of proteasomal degradation, creates an external
robustness of the p53-mediated ablation of c-Myc. This ensures
that downregulation of c-Myc by p53 is achieved irrespective of
the particular combination of mutations in a given cell. Dysfunc-
tion of one mechanism of c-Myc downregulation by p53, such
as, for example, loss of FBXW7/hCDC4, constitutive activation
of Akt, MYC gene translocation, or mutation, will be compen-
sated for by other branches in the hierarchy. Since tumors are
often dependent on deregulated c-Myc expression (Felsher
and Bishop, 1999), its elimination might be an essential compo-
nent for anticancer therapies targeting p53.
We have analyzed the effect of p53 on a number of oncogenic
factors, but we possibly obtained only a glimpse of the whole
picture of p53-induced effects. Systems biology studies aimed
at characterizing the whole proteome of cancer cells upon p53
activation will help to better characterize the p53 network in
the future.
Rescue of p53 tumor suppressor function by blocking the
inhibitory role of MDM2 is a promising strategy by which to
combat cancer that is pursued both in academia and industry
(Lain et al., 2008; Yang et al., 2005). However, the question
remains as to whether p53 reactivation by small molecules will
be harmful for normal cells. A number of studies pointed toward
the ability of p53 to kill cancer cells without detrimental effects in
normal cells in vitro, although the mechanism of this phenom-
enon has not been defined (Selivanova, 2004). We have demon-
strated that p53 induction by RITA in the absence of oncogene
expression in nontransformed cells is transient and does not
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study extends these observations and indicates that the ability
of p53 to target oncogene addiction might provide selective
killing of cancer cells by molecules reactivating p53. We specu-
late that tumor cells might be particularly sensitive to p53 reacti-
vation due to p53’s ability to target oncogene addiction and
disable survival programs that tumor cells are critically depen-
dent on. Consequently, normal cells that are not dependent on
oncogenes for their survival will remain largely unaffected.
Additional studies including animal models will be required to
address this issue.
Side effects and development of drug resistance remain
a formidable barrier for the successful treatment of cancer.
One way to solve these problems is to apply drug combinations,
because multitargeted therapies will decrease the chance of
mutations conferring resistance. At the same time, drug combi-
nations that produce synergistic effects will allow a lower dose to
be used and thus will decrease nonspecific toxicity of drugs.
Combining targeted drugs in a more effective manner is a chal-
lenge; therefore, it becomes increasingly important to decipher
the interactions between signaling pathways in cancer cells.
Our data might help to identify pathways and/or factors whose
targeting can provide a synergy with p53-reactivating
compounds. Importantly, we show that combination of a low
dose of p53-reactivating compound with inhibition of the
PI(3)K/Akt pathway, c-Myc, or Mcl-1 produced a synergistic
effect. Further work aimed at detailed characterization of molec-
ular events upon p53 activation might help to guide rational
development of more efficient and less toxic drug combinations.
EXPERIMENTAL PROCEDURES
Cell Lines, Plasmids, shRNA, and siRNA
Colon carcinoma HCT116, HCT116 TP53/, and HCT116CDC4/ cells were
gifts from B.Vogelstein and K.W. Kinzler. Osteosarcoma U2OS cells stably
transfected with a Tet-regulatable c-Myc construct were obtained from J. Bar-
tek. Translational reporter pcDNA/REN/HCV/FF was obtained from J. Pelletier.
The eIF4E expression vector pcDNA3-3HA-meIF4Ewt was a gift from N. So-
nenberg. Lentiviral p53 shRNA constructs were obtained from A. Jochemsen
and from P. Chumakov. MYC siRNA was kindly provided by L.-G. Larsson,
MCL-1 siRNA was purchased from Santa Cruz, and GFP siRNA was purchased
from Oligoengine. Plasmid DNA and siRNA transfections were performed with
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.
Cell viability assays were performed as we described (Enge et al., 2009).
Reagents
RITA was obtained from the National Cancer Institute (NCI) and was used at
a concentration of 1 mM, unless otherwise stated. The proteasomal inhibitor
MG132 was used at a concentration of 20 mM, the inhibitor of GSK3b kinase
B1686 BIO was used at 5 mM, and the PI3-kinase inhibitor LY294002 was
used at 20 mM (all from Sigma). Z-VAD-fmk (R&D Systems) was used at
20 mM concentration, and the p53 inhibitor PFTa, a gift from A. Gudkov, was
used at 10 mM concentration.
Genome-Wide Analysis of Gene Expression Profiles
Analysis of gene expression profiles in HCT116 cells was performed as
described (Enge et al., 2009). Microarray analysis in MCF7 cells treated with
1 mM RITA for 2–24 hr was performed by using hgu133a2 chips (Affymetrix).
Raw data (.cel files) were analyzed by using the ExPlain software package
(Wingender et al., 2007). Normalization and the quality control of the data
were done with MAS 5.0 (‘‘Quantiles,’’ normalization method; ‘‘PM only,’’ PM
correction method). The data from arrays representing 2-4, 6-8-10, and
12-14-16 hr (indicated in Figure 1B as 2, 8, and 16 hr, respectively) were pooledtogether, and the average fold change was calculated by using the t test
method implemented in R package.
In Vitro Assays
For quantitative real-time reverse transcriptase-PCR analysis, mRNA from
cells was isolated by using the RNeasy Kit (Quiagen). mRNA quantification
was performed by using a fluorescence-based real-time RT-PCR technology
(Power SYBR Green PCR Master Mix [ABI]). Primer sequences are described
in Table S1. The preparation of cell extracts and western blot were performed
according to standard procedures. Antibodies for immunoblotting were as
follows: Phospho-Akt (anti-Ser473, 587F11), Akt, mTOR, Phospho-GSK3ab
(27C10), and Phospho-c-Myc (Ser62/Thr58) were from Cell Signaling; p53
(DO1), IGF-IR (C-20), Mcl-1 (S-19), c-Myc (N-262), PARP (H-250), GADD45a
(C4), b-catenin, Bcl-2 (C-2), cyclin E (HE-12), survivin (FL-142), Fas (N-18),
and MDM2(SMP14) were from Santa Cruz; b-actin (Sigma) and Phospho-
mTOR (S2448) were from R&D Systems; p21 was from Beckton Dickinson;
Noxa and PUMA were from Calbiochem; and Histone H3 was from Abcam.
Secondary HRP-conjugated antibodies and Super Signal West Dura Extended
Duration Substrate were from Pierce. To detect human c-Myc in xenografts,
we used c-Myc (A-14) antibody (Santa-Cruz). Akt kinase activity was assessed
by using the Nonradioactive Akt Kinase Assay Kit (Cell Signaling) according to
the manufacturer’s instructions. To measure CAP-dependent translation, cells
were transiently transfected with the luciferase translational reporter construct
pcDNA/REN/HCV/FF, and 24–48 hr after transfection the signal from Firefly
luciferase was detected by using the Dual-Glo Luciferase Assay System
(Promega). Small-scale biochemical fractionation to purify cytoplasmic,
nuclear, and chromatin fractions was performed as described (Wysocka
et al., 2001). Chromatin immunoprecipitation (ChIP) was performed as
described (Enge et al., 2009), and the ChIP primers are presented in Table S1.
Animal Experiments
The Northern Stockholm Animal Ethical Committee approved all animal
studies, and animal care was in accordance with Karolinska Institutet guide-
lines. Male SCID mice, 4–6 weeks old, were implanted subcutaneously with
13 106 HCT116 or HCT116 TP53/ cells in 90% Matrigel (Becton Dickinson).
Palpable tumors were established 7 days after cell injection; at this point, we
injected 1 mg/kg RITA in tumors in a total volume of 100 ml phosphate-buffered
saline.
Calculation of Expected Additive Effect
The expected additive effect was calculated using the following formula: D =
A + (B  A) + (C  A), where D is the expected additive effect, A is the
percentage of apoptosis in untreated cells, and B and C are the percentages
of apoptosis in cells upon first or second treatments, respectively.
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